Clinical trial / 2019
Oral saffron supplementation modestly improved visual acuity and electroretinogram parameters in adults with mild to moderate age-related macular degeneration.
A randomized, double-blinded, placebo-controlled crossover trial evaluated the effects of 20 mg/day oral saffron versus placebo for 3 months each in 100 adults with mild/moderate age-related macular degeneration. Mean BCVA improved by 0.69 letters (p = 0.001) and mean-pooled mfERG latency decreased by 0.17 ms (p = 0.04) on saffron compared to placebo. In participants also taking AREDS supplements, mean BCVA improved by 0.73 letters (p = 0.006) and mfERG response density improved by 2.8% (p = 0.038). Adverse events did not differ significantly between groups (p > 0.10).
- Study type
- Randomised, double-blinded, placebo-controlled crossover trial
- Who was studied
- 100 adults (> 50 years) with mild/moderate age-related macular degeneration
- What was measured
- Best-corrected visual acuity (BCVA) and multifocal electroretinogram (mfERG) response density and latency
THE PAPER
Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial.
Broadhead GK, Grigg JR, McCluskey P, Hong T, Schlub TE, Chang AA. Graefes Arch Clin Exp Ophthalmol, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.